ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia

Affiliations

• ¹ Department I for Internal Medicine, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, University of Cologne, Cologne, Germany.
• ² Medical School, Università Vita-Salute San Raffaele, Milan; Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
• ³ Department of Haematology, Rigshospitalet, Copenhagen, Denmark.
• ⁴ Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
• ⁵ Division of Hematology, Luzerner Kantonsspital, Luzern, Switzerland.
• ⁶ Department I for Internal Medicine, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, University of Cologne, Cologne, Germany; Cluster of Excellence-Cologne Excellence on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
• ⁷ Department of Oncology, Skåne University Hospital and Lund University, Lund, Sweden.
• ⁸ Institute of Experimental Cancer Research, Comprehensive Cancer Center Ulm (CCCU), University Hospital of Ulm, Ulm, Germany.